Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson’s disease: a national assessment of US office-based physician visits

References

• Suchowersky O, Reich S, Perimutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology. 2006;66(7):968–975.
   PubMed Web of Science ®Google Scholar
• De Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5(6):525–535.
   PubMed Web of Science ®Google Scholar
• Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–189.
   PubMed Web of Science ®Google Scholar
• Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2001;13(2):187–196.
   PubMed Web of Science ®Google Scholar
• Hsu YT, Liao CC, Chang SN, et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriat Psychiatry. 2015;23(9):934–940.
   PubMed Web of Science ®Google Scholar
• Veazey C, Aki SO, Cook KF, Lai EC, Kunik ME. Prevalence and treatment of depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(3):310–323.
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8(3):193–197.
   PubMed Web of Science ®Google Scholar
• Ng A, Chander RJ, Tan LC, Kandiah N. Influence of depression in mild Parkinson’s disease on longitudinal motor and cognitive function. Parkinsonism Relat Disord. 2015;21(9):1056–1060.
   PubMed Web of Science ®Google Scholar
• Ravina B, Camiciolo R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–347.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1992;55(5):377–382.
   PubMed Web of Science ®Google Scholar
• Müller B, Assmus J, Herlofson, Larsen JP, Tysnes OB. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(11):1027–1032.
   PubMed Web of Science ®Google Scholar
• Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand. 2004;110(2):118–123.
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology. 2006;66:996–1002.
   PubMed Web of Science ®Google Scholar
• Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57(10):449–454.
   PubMed Web of Science ®Google Scholar
• Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson’s disease. Neurol Sci. 2008;29:391–395.
   PubMed Web of Science ®Google Scholar
• Antonini A, Tesei S, Zecchinelli A, et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson’s disease and depression: effect on quality of life. Mov Disord. 2006;21:1119–1122.
   PubMed Web of Science ®Google Scholar
• Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003;23:509–513.
   PubMed Web of Science ®Google Scholar
• Dell’Angello G. SSRIs do not worsen Parkinson’s disease: evidence form an open label, prospective study. Clin Neuropharmacol. 2001;24:221–227.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology. 2000;55:1216–1218.
   PubMed Web of Science ®Google Scholar
• Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson’s disease treated with L-dopa. Clin Neuropharmacol. 2002;25:21–24.
   PubMed Web of Science ®Google Scholar
• Sclar DA, Robison LM, Skaer TL, Galin RS. Depression in Parkinson’s disease: a national survey of office-based visits 1990-1995. Int J Geriatr Psychopharmacol. 1998;1:216–219.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. Ambulatory health care data: NAMCS scope and sample design [updated 2010 January 15]. Available from: https://www.cdc.gov/nchs/ahcd/ahcd_scope.htm. Accessed July 27, 2017.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. NAMCS data collection and processing [updated 2011 August 15]. Available from: https://www.cdc.gov/nchs/ahcd/ahcd_data_collection.htm. Accessed July 27, 2017.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. Questionnaires, datasets, and related documentation. Public-use data files (1973-2015) [updated August 31, 2017]. Available from: https://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed September 18, 2017.
   Google Scholar
• Barnett ML, Linder JA, Clark CR, Sommers BD. Low-value medical services in the safety-net population. JAMA Intern Med. 2017;177(6):829–837.
   PubMed Web of Science ®Google Scholar
• Mafi JN, Wee CC, Davis RB, Landon BE. Association of primary care practice location and ownership with the provision of low-value care in the United States. JAMA Intern Med. 2017;177(6):838–845.
   PubMed Web of Science ®Google Scholar
• Mojtabai R. Does depression screening have an effect on the diagnosis and treatment of mood disorders in general medical settings? An instrumental variable analysis of the National Ambulatory Medical Care Survey. Med Care Res Rev. 2011;68(4):462–489.
   PubMed Web of Science ®Google Scholar
• Swanoski MT, Little MM, St Hill CA, Ware KB, Chapman S, Lutfiyya MN. Potentially inappropriate medication prescribing in U.S. older adults with selected chronic conditions. Consult Pharm. 2017;32(9):525–534.
   PubMedGoogle Scholar
• Gerlach LB, Olfson M, Kales HC, Maust DT. Opioids and other central nervous system-active polypharmacy in older adults in the United States. J Am Geriatr Soc. 2017;65(9):2052–2056.
   PubMed Web of Science ®Google Scholar
• Akincigil A, Matthews EB. National rates and patterns of depression screening in primary care: results from 2012 and 2013. Psychiatr Serv. 2017;68(7):660–666.
   PubMed Web of Science ®Google Scholar
• Patel SR, Humensky JL, Olfson M, Simpson HB, Myers R, Dixon LB. Treatment of obsessive-compulsive disorder in a nationwide survey of office-based physician practice. Psychiatr Serv. 2014;65(5):681–684.
   PubMed Web of Science ®Google Scholar
• Gerhard T, Akincigil A, Correll CU, Foglio NJ, Crystal S, Olfson M. National trends in second-generation antipsychotic augmentation for nonpsychotic depression. J Clin Psychiatry. 2014;75(5):490–497.
   PubMed Web of Science ®Google Scholar
• Rege S, Sura S, Aparasu RR. Atypical antipsychotic prescribing in patients with depression. Res Social Adm Pharm. 2017 Epub Aug 2.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. 2014 NAMCS micro-data file documentation. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/doc2014.pdf. Accessed July 28, 2017.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. NAMCS estimation procedures [updated November 6, 2015]. Available from: https://www.cdc.gov/nchs/ahcd/ahcd_estimation_procedures.htm. Accessed September 18, 2017.
   Google Scholar
• U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. 2013 NAMCS micro-data file documentation. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/doc2013.pdf. Accessed September 18, 2017.
   Google Scholar
• Center Watch. FDA Approved Drugs for Psychiatry/Psychology. Available from: https://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/17/psychiatry-psychology. Accessed July 3, 2017.
   Google Scholar
• U.S. Centers for Medicare & Medicaid Services, Medicaid Integrity Group. Antidepressant medications: use in adults. August 2013. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-adult-factsheet.pdf. Accessed September 18, 2017.
   Google Scholar
• Pontone GM, Williams JR, Anderson KE, et al. Pharmacologic treatment of anxiety disorders in Parkinson’s disease. Am J Geriatr Psychiatry. 2013;21(6):520–526.
   PubMed Web of Science ®Google Scholar
• Wong J, Motulsky A, Abrahamowicz M, et al. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603.
   PubMed Web of Science ®Google Scholar
• Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry. 2005;76 (Suppl 1):i48–i52.
   PubMedGoogle Scholar
• Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253:601–607.
   PubMed Web of Science ®Google Scholar
• March GG, Markham CH. Does levodopa alter depression and psychopathology in Parkinsonism patients? J Neurol Neurosurg Psychiatry. 1973;36:925–935.
   PubMed Web of Science ®Google Scholar
• Choi C, Sohn YH, Lee JH, Kim J. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson’s disease. J Neurol Sci. 2000;172:12–16.
   PubMed Web of Science ®Google Scholar